Table 1

Patient characteristics classified by disease progression

CharacteristicaValue for patients with:P
CH (n = 25)LC (n = 29)HCC (n = 25)
No. male/female14/1110/1912/130.278
Age (yr) (mean ± SD)63.4 ± 14.666.5 ± 9.268.4 ± 8.20.539
Platelets (10−4/mm3) (mean ± SD)16.1 ± 4.79.8 ± 3.911.1 ± 5.1<0.001
Albumin (g/dl) (mean ± SD)4.4 ± 0.33.9 ± 0.63.5 ± 0.5<0.001
γ-GTP (IU/liter) (median [range])53.5 (12–230)38.0 (12–108)40.8 (15–110)0.845
T. chol. (mg/dl) (mean ± SD)161 ± 28148 ± 30140 ± 280.053
HCV RNA (kIU/ml) (median [range])7,047 (501–19,953)5,369 (126–25,119)8,421 (110–25,119)0.288
Alpha-fetoprotein (ng/ml) (median [range])5.0 (1.1–16.5)32.2 (1.0–252.6)614.8 (1.9–13,418)<0.001
AST (IU/liter) (mean ± SD)42.4 ± 17.851.1 ± 23.559.1 ± 28.20.046
ALT (IU/liter) (mean ± SD)46.6 ± 23.143.9 ± 29.360.7 ± 52.70.263
No. with R/(Q/H) at core aa 70b19/612/178/170.005
No. with L/(M/C) at core aa 91b17/819/1015/100.834
No. of ISDR mutations (median [range])b0.8 (0–6)1.2 (0–7)0.9 (0–8)0.799
No. of IRRDR mutations (median [range])b4.9 (1–10)4.7 (2–9)5.2 (1–12)0.962
No. with TT/non-TT at IL28B SNP (rs8099917)18/717/1214/110.458
No. without/with a history of interferon therapy14/1116/1315/100.933
  • a T. chol., total cholesterol; AST, aspartate transaminase; ALT, alanine aminotransferase.

  • b Core aa 70, core aa 91, the interferon sensitivity-determining region (ISDR), and the interferon-ribavirin resistance-determining region (IRRDR) were dominant viral sequences determined by direct sequencing.